- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MRI reveals when cognitive impairment will advance
Swiss researchers used susceptibility-weighted MRI and an artificial intelligence technique to help identify which individuals with mild cognitive impairment will continue to decline.
Swiss researchers used susceptibility-weighted MRI and an artificial intelligence technique to help identify which individuals with mild cognitive impairment will continue to decline.
Susceptibility-weighted MRI measures magnetic susceptibility phase-effect differences between tissues. Using the technique, researchers were able to view details of the blood vessels in the brain, including microhemorrhages and microbleeds.
The scans revealed microbleeds in 33% subjects with stable mild cognitive impairment. They found microbleeds in 54% of those with progressive cognitive impairment and in 14% of the control group. The study appeared in Radiology.
The researchers also analyzed the data with support vector technology algorithms to identify patterns within a group and create classifications. By adding the support vector technology to the baseline MRI data the researchers were able to distinguish patients with mild cognitive impairment with 85% accuracy.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
